Market Size (2016)
2016
$254.89M
Healthcare
Pemphigus Vulgaris Market
By Segment, By Region, And Segment Forecasts, 2016 – 2027
Vertical: HealthcareBase Year: 201812 Sections
Executive Summary
Pemphigus Vulgaris Market — Snapshot
Projected (2027)
2027
$756.53M
CAGR (2016–2027)
10.4%
10.4%Key Players
107+
A pemphigus vulgaris is a type of autoimmune disease in which the antibodies produced against the bacteria attack the normal cells and causes skin problems. Pemphigus vulgaris equally affects man and woman but middle and old age people are more likely to develop this condition.
The key factors responsible for influencing the market growth are the increasing prevalence of pemphigus vulgaris, increasing geriatric population. Increase in geriatric population are also estimated to drive the market during the forecast period. However, factors such as high cost related to treatment and lack of awareness are expected to restrain the market growth
Key Insight
The Pemphigus Vulgaris Market market is projected to grow at a CAGR of 10.4% from 2016 to 2027.
Market Performance Trend
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Scope & Coverage
What this report covers
- Geographic Coverage: This analysis covers 4 regions: Europe, Asia Pacific, Rest of the World, Americas.
- Market Segmentation: The market is analyzed across 5 segments: Immunosuppressants, Corticosteroids, Intravenous Immunoglobulin (IVIG) Therapy, Biological Therapies, Others. Forecasts are provided for each segment from 2016 to 2027.
- Competitive Landscape: 107 leading companies are profiled, covering market positioning, strategies, and recent developments.
Market Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Overview
Pemphigus Vulgaris Market — Growth Trajectory
The scope of the global pemphigus vulgaris market study includes market size analysis and a detailed analysis of the manufacturer’s products and strategies. The market has been segmented based on treatment, route of administration, end user, end user, and region.
Pemphigus Vulgaris Market — Growth Trajectory
Immunosuppressants
Corticosteroids
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Size Trend (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Dimensions
How this market is segmented
- Treatment Type Treatment Type is broken down into: Corticosteroids, Immunosuppressants, Biological Therapies, Intravenous Immunoglobulin (IVIG) Therapy, Others.
- Route of Administration Route of Administration is broken down into: Oral, Subcutaneous, Intravenous.
- End User End User is broken down into: Hospitals & Clinics, Specialty Dermatology Clinics, Research & Academic Laboratories.
Geographic Analysis
Regional market breakdown
- Europe Europe market size reached $97.90M in 2016 and is projected to reach $290.89M by 2027, growing at a CAGR of 10.4%.
- Asia Pacific Asia Pacific market size reached $37.11M in 2016 and is projected to reach $112.58M by 2027, growing at a CAGR of 10.6%.
- Rest of the World Rest of the World market size reached $11.34M in 2016 and is projected to reach $27.33M by 2027, growing at a CAGR of 8.3%.
- Americas Americas market size reached $108.54M in 2016 and is projected to reach $325.73M by 2027, growing at a CAGR of 10.5%.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansResearch Methodology
Pemphigus Vulgaris Market — How We Researched This Market
This report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2018
Historical Period
2016 – 2018
Forecast Period
2018 – 2027
Primary Interviews
150+
Research Process
Historical data (2016–2018) and forecast period (2018–2027)
1
Problem Definition
- Market scoping
- Objective setting
- Framework design
2
Secondary Research
- Literature review
- Data mining
- Trend analysis
3
Primary Research
- Expert interviews
- Field visits
- Surveys
4
Data Analysis
- Quantitative modeling
- Statistical testing
- Validation
5
Insights & Reporting
- Synthesis
- Recommendations
- Visualization
Research Depth
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Historical vs. Forecast Data
Historical (observed)
Forecast (modelled)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansCompetitive Landscape & Porter's Five Forces
Pemphigus Vulgaris Market — Competitive Analysis
Bargaining Power of Suppliers
argaining power of suppliers in the pemphigus vulgaris market is medium. In global pemphigus vulgaris industry, suppliers are raw materials manufacturers and, intermediate original equipment manufacturers (OEMs). There is a high number of suppliers in the global pemphigus vulgaris market thus leading to a moderate amount of bargaining power in the market. Switching cost of these suppliers is also medium as the suppliers tend to enter into long-term associations with the manufacturers.
Bargaining Power of Buyers
The bargaining power of buyers is low to medium in the pemphigus vulgaris market. Patients are the major buyers for the market. The presence of buyers in the market is high due to the increasing prevalence of autoimmune diseases and the growing burden of immunological diseases. In addition, buyers are price sensitive, which moderately affects their bargaining power in the market. There is a presence of a high number of antibacterial drug manufacturers in the world, which provides products at a low cost. Additionally, switching cost is moderate for buyers as many alternative treatments are available at an effective cost.
Threat of New Entrants
The threat of new entrants is medium to high in the pemphigus vulgaris market. Any company manufacturing the drug for pemphigus vulgaris which is trying to enter the market is required to abide by mandatory regulatory standards. The pemphigus vulgaris drug manufacturing market is also characterized by a high degree of brand loyalty where establishing a brand name is difficult for newcomers. However, government support and presence of huge opportunities in the market has encouraged many players to invest in this lucrative market. These factors are responsible for reducing the barrier for entrance on new companies which can be a major threat for the current companies.
Threat of Substitutes
The threat of substitutes in the global pemphigus vulgaris market is Medium. Substitutes are the different types of generic and other drugs, which completely dependent on the efficacy and the cost of the drug. Buyer propensity to substitute is low as most of the medical professionals prescribe a limited number of drugs.
Intensity of Rivalry
The degree of competition in the pemphigus vulgaris market is medium. The moderate degree of product differentiation among existing players increases the intensity of rivalry in the market. Pemphigus vulgaris drug manufacturing companies are trying to develop less expensive drugs to make treatment more affordable in the developing region. Moreover, brand loyalty moderately affects the market as buyers are more inclined towards established manufacturers. To overcome the competition, players are focusing on the development of new products to withstand the increasing competition. Moreover, the players are also developing advanced techniques for differentiating their product from their rivals.
Quantitative Analysis
Regional Breakdown
Regional market breakdown for Pemphigus Vulgaris Market.
Regional Market Size (USD Mn)
Market estimates by geography (2027)
USD Mn
InsightAmericas leads with $325.73M by 2027, while Asia Pacific is projected to grow fastest at a 10.6% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansRegional Market Data
| REGION | 2016 | 2018 | 2027 | CAGR | SHARE |
|---|---|---|---|---|---|
| Europe | $97.90M | $193.72M | $290.89M | 10.4% | 38% |
| Asia Pacific | $37.11M | $74.27M | $112.58M | 10.6% | 15% |
| Rest of the World | $11.34M | $20.13M | $27.33M | 8.3% | 4% |
| Americas | $108.54M | $215.95M | $325.73M | 10.5% | 43% |
| Total | $254.89M | $504.07M | $756.53M | 10.4% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSegment Revenue (2027)
Immunosuppressants
Corticosteroids
Intravenous Immunoglobulin (IVIG) Therapy
Biological Therapies
Others
067133200266
Segment Market Share
- Immunosuppressants32%
- Corticosteroids27%
- Intravenous Immunoglobulin (IVIG) Therapy24%
- Biological Therapies13%
- Others4%
Total Market Size
$756.54M
Market by Segment (2027)
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Immunosuppressants | $241.58M | 10.4% | 77% |
| Corticosteroids | $205.28M | 10.4% | 72% |
| Intravenous Immunoglobulin (IVIG) Therapy | $179.54M | 10.4% | 47% |
| Biological Therapies | $96.83M | 10.4% | 85% |
| Others | $33.31M | 10.4% | 53% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansEmpower your Business
with InsightsSave over 20% on
with Insights
Save over 20% on
Annual Subscription
See plans for professionals or small and medium businesses.
Analytics
Pemphigus Vulgaris Market — Key Findings
Analytical insights on Pemphigus Vulgaris Market covering market dynamics, competitive landscape, and strategic outlook.
Key Analytical Findings
The Pemphigus Vulgaris Market market is projected to reach $756.53M by 2027, growing at 10.4% CAGR. The Immunosuppressants segment holds the largest share.
Market Dynamics
A pemphigus vulgaris is a type of autoimmune disease in which the antibodies produced against the bacteria attack the normal cells and cause skin problems. Pemphigus vulgaris equally affects man and woman but middle and old age people are more likely to develop this condition.
The increasing prevalence of pemphigus vulgaris globally, growing financial support by various private and government organizations for research of diseases, and increasing geriatric population are driving the global pemphigus vulgaris market. However, lack of awareness among countries and the high cost of treatment are expected to hamper the growth of this market during the forecast period. Nevertheless, advancements in treatments are set to be a lucrative opportunity for the growth of this market in the near future.
Market Drivers
Pemphigus vulgaris is one of the life-threatening autoimmune skin disorders that occurs due to various reasons such as bacterial infection, increasing pollution, and side effects of some medications. According to the National Organization for Rare Disorders (NORD), 2015, the prevalence of pemphigus was high within the US and Europe, with approximately 0.7 to 5 people per 1,000,000 per year in the overall population. It was also mentioned that pemphigus foliaceous, a form of pemphigus vulgaris, has a high prevalence in Africa and some rural areas in the world. Similarly, according to the International Pemphigus & Pemphigoid Foundation, the incidence of pemphigus was high within China with approximately 0.5 to 3.2 people per 100,000 per year in the overall population.
According to the International Pemphigus & Pemphigoid Foundation, it was predicted that approximately 40,000 to 50,000 people across the world and 2,500 people in the US were encountered with pemphigus disorder in 2017. The increase in the prevalence of pemphigus vulgaris across the world is expected to drive market growth during the forecast period. Thus, the high number of incidences of pemphigus vulgaris would support market growth during the forecast period.
Market Opportunities
The number of people suffering from pemphigus vulgaris is increasing globally, and the complication and severity related to this condition are also rising. According to the South African Dental Association (SADA) 2018, the study on oral pemphigus vulgaris with skin and ocular involvement mentioned that laser therapy could be used as an alternative method to treat pemphigus vulgaris which is an effective method with fewer side effects. The increase in advancements in treatments is likely to enhance the market growth.
Market Restraints
Pemphigus vulgaris is most common in developing countries than in developed countries, as most of the population living in developing countries are not aware of dermatological problems. The number of cases registered in developing countries is high as compared to the cases occurring in developed countries. According to the National Organization for Rare Disorders (NORD) 2015 Endemic pemphigus (Fogo Selvagem), a form of pemphigus occurred in a large number of people living in Central and South America, especially countryside areas of Brazil and also occurred in different rural areas of the world. The lack of awareness about the treatment among the population is likely to hinder the market growth.
Market Challenges
The initial step in the therapeutic management of pemphigus vulgaris is to control diseases, restore the affected areas, and reduce the damage or spreading of infections. The main challenge in the long-term treatment is the side effects associated with the treatment and adverse effects of immunosuppressive agents. According to the National Center for Biotechnology Information 2016, side-effects associated with the use of corticosteroids for the treatment of pemphigus vulgaris include osteoporosis, diabetes, tension, increased weight, abnormal liver function test, fungal and viral infection, hyperkalemia, cataract, and myopathy. Such side effects and complications of treatments could affect the pemphigus vulgaris market negatively.
Strategic Outlook and Future Directions
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Market Value by Segment (2027)
Value (USD Mn)
Immunosuppressants
Corticosteroids
Intravenous Immunoglobulin (IVIG) Therapy
Biological Therapies
Others
Companies
Key companies profiled in Pemphigus Vulgaris Market
Profiles of 107 companies operating in the Pemphigus Vulgaris Market market, including revenue, employee count, and market positioning where available.
Showing 107 of 107 companies
CABALETTA
CABALETTA BIO
Healthcare
Company Headquarters: Philadelphia, US Founded: 2017 Workforce: ~ 10-50 Company Working: Cabaletta Bio (Cabaletta) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Our proprietary technology utilizes chimeric autoantibody receptor, or CAAR, T cells that are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies (pathogenic B cells) while sparing normal B cells. The company’s CABA platform, has applicability across more than two dozen B cell-mediated autoimmune diseases.
RevenueN/A
Employees50
Market CapN/A
Founded2016
Philadelphia, US
INTAS PHAR
INTAS PHARMACEUTICALS LTD (ACCORD HEALTHCARE)
Healthcare
Company Headquarters: Ahmedabad, India Founded: 1984 Workforce: ~ 350 Company Working: Intas Pharmaceuticals Ltd (Intas) is a vertically integrated global pharmaceutical formulation developing, manufacturing, and marketing company. Intas has set up a network of subsidiaries, under the umbrella named Accord Healthcare to operate in global markets. Accord's portfolio comprises a multitude of different pharmaceutical forms, including, tablets, capsules, cytotoxic injectables, non- cytotoxic (ampoules), and controlled drugs.
RevenueN/A
Employees350
Market CapN/A
Founded1983
Ahmedabad, India
PRINCIPIA
PRINCIPIA BIOPHARMA
Healthcare
Company Headquarters: South San Francisco, CA (US) Founded: 2008 Workforce: ~57 Company Working: Principia Biopharma (Principia) functions as a late-stage biopharmaceutical company focused on developing novel therapies for serious immune mediated diseases. The company offers and develops drugs for the treatment of cancer. The company serves the US market. Principia Biopharma patented tailored covalency platform allows to develop and design small covalent molecules.
RevenueN/A
Employees57
Market CapN/A
Founded2007
South San Francisco, CA (US)
BIOGEN INC
BIOGEN INC.
Healthcare
Company Headquarters: Massachusetts, US Founded: 1978 Workforce: 7,800 Company Working: Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers drugs for the treatment of multiple sclerosis, plaque psoriasis spinal muscular atrophy, non-Hodgkin's lymphoma, Chronic Lymphocytic Leukemia (CLL), and among other conditions. The company offers products through its sales force and marketing groups. It has strategic collaborations with Ionis Pharmaceuticals to develop drug candidates for neurological diseases. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. The firm has a strong presence in North America, Europe, Asia-Pacific, and
Revenue$9.8B
Employees7,800
Market CapN/A
Founded1977
Massachusetts, US
ARGENX SE
ARGENX SE
Healthcare
Company Headquarters: Breda, The Netherlands Founded: 2008 Workforce: 105 Company Working: argenx SE is a clinical-stage biotechnology company. It is developing a pipeline of differentiated antibody-based therapies for the treatment of autoimmune diseases and cancer. The company focuses on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known to treat diseases with significant unmet medical needs. It has a strong presence in Luxembourg, Denmark, Switzerland, and the Netherlands.
Revenue$0.0B
Employees105
Market CapN/A
Founded2007
Breda, The Netherlands
F. HOFFMAN
F. HOFFMANN-LA ROCHE LTD
Healthcare
Incorporated in 1896 and headquarters in Basel, Switzerland; F. Hoffmann-La Roche AG is the world's biggest biotech organization, with genuinely differentiated solutions in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is additionally the world pioneer in vitro diagnostics and tissue-based cancer diagnostics, and a leader in diabetes management. The consolidated qualities of pharmaceuticals and diagnostics under one rooftop have made Roche the pioneer in personalized healthcare. The products offered by the company helps in tapping in the world’s two third of all the diseases which are either not treated effectively or not treated at all. The company offers various products in the Pharmaceutical, Diagnostics and research industry. Geographically the company operates in North America, Europe, South America, Africa, Asia and Oceania. As of 2015 F. Hoffmann-La Roche AG had a head count of 91,700 + employees world wide Roche Strategy – a methodology that intends to fit the right treatment to every patient in the most ideal way that could be available dedicated on developing innovative diagnostic tests and medicines which will help their patients and the world.
Revenue$63.3B
EmployeesN/A
Market CapN/A
FoundedN/A
United States, North America
Page 1 of 18
…
Go to page
Powering the world's best teams.
From next-gen startups to established enterprises.
What our clients say
Trusted by forward-thinking businesses
for data-driven intelligence
Noah Malgeri
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Michael Robert
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Bong Lau
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Mark Irwin
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
Jason Lee
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Akif Moroglu
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Noah Malgeri
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Michael Robert
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Bong Lau
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Mark Irwin
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
Jason Lee
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Akif Moroglu
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Pemphigus Vulgaris Market
Starting from
$4,950